A novel model for predicting the progression of HCC that incorporates TSH levels was recently suggested by Yu et al. The authors studied a retrospective (n = 1005) and a prospective (n = 77) cohort with HCC to develop and validate the efficacy of a novel prognostic model leveraging TSH levels and three more variables (Barcelona Clinic Liver Cancer (BCLC) stage, the presence of portal vein tumor thrombus, an alpha-fetoprotein level). The gene discussed is AFP; the disease is hepatocellular carcinoma.